Request Demo
Last update 24 Dec 2025
Insulin aspart biosimilar(Geropharm LLC)
Last update 24 Dec 2025
Overview
Basic Info
Drug Type Biosimilar, Peptide Hormone |
Synonyms Insulin aspart Biosimilar (Geropharm LLC), 门冬胰岛素生物类似药（Geropharm LLC）, GP-40071 + [2] |
Target |
Action agonists |
Mechanism INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Russia (01 Nov 2023), |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 4857
The sequence is quoted from: *****
Sequence Code 31953
The sequence is quoted from: *****
Related
4
Clinical Trials associated with Insulin aspart biosimilar(Geropharm LLC)NCT04226105
An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of GP40081 (OOO "GEROPHARM", Russia) Compared to NovoMix® 30 FlexPen® (Novo Nordisk A/S, Denmark) in Type 2 Diabetes Mellitus Patients
NCT04079413
An Open-label, Randomized, Multi-center, Parallel-group Clinical Trial Comparing the Efficacy and Safety of GP40071 (OOO "GEROPHARM", Russia) Compared to NovoRapid® Penfill® (Novo Nordisk A/S, Denmark) in Type 1 Diabetes Mellitus Patients
NCT04184492
A Randomized Double Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of GP-40081 (LLC "GEROPHARM", Russia) Versus NovoMix® 30 Penfill® (Novo Nordisk) in Healthy Subjects Using the Euglycemic Clamp Technique
100 Clinical Results associated with Insulin aspart biosimilar(Geropharm LLC)
Login to view more data
100 Translational Medicine associated with Insulin aspart biosimilar(Geropharm LLC)
Login to view more data
100 Patents (Medical) associated with Insulin aspart biosimilar(Geropharm LLC)
Login to view more data
3
Literatures (Medical) associated with Insulin aspart biosimilar(Geropharm LLC)01 Dec 2022Journal of comparative effectiveness research
The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix
®
30 in Type 2 diabetes patients
Article
Author: Kovalik, Vladislav V ; Drai, Roman V ; Andreeva, Alena T ; Makarenko, Igor E ; Magruk, Maxim A ; Parfenova, Tatiana M ; Mayorov, Alexander Y ; Alpenidze, Diana N ; Karonova, Tatiana L ; Zinnatulina, Bella R ; Grigorjeva, Irina V
01 Aug 2022Clinical pharmacology in drug development
Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure
Article
Author: Mayorov, Alexander Y. ; Kulesh, Viktoria S. ; Andreeva, Alena T. ; Karonova, Tatiana L. ; Drai, Roman V. ; Kovalik, Vladislav V. ; Makarenko, Igor E. ; Dorotenko, Artem R.
01 Jun 2021Journal of comparative effectiveness researchQ4 · MEDICINE
Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid
®
Penfill
®
) in Type 1 diabetes mellitus
Q4 · MEDICINE
Article
Author: Magruk, Maxim A ; Mosikian, Anna A ; Karonova, Tatiana L ; Khmelnitski, Oleg K ; Grigoryeva, Irina V ; Zyangirova, Svetlana T ; Mayorov, Alexander Y ; Drai, Roman V ; Myshkovets, Anton ; Parfenova, Tatyana M
100 Deals associated with Insulin aspart biosimilar(Geropharm LLC)
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | Russia | 01 Nov 2023 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 1 | Phase 3 | Russia | 03 Jun 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 264 | kzywtaugvf(qpopeylyed) = wkkgehblxd ohekllcxge (nnjwvhntsr ) | Similar | 01 Jun 2021 | |||
NovoRapid® | kzywtaugvf(qpopeylyed) = htkffcugfa ohekllcxge (nnjwvhntsr ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free